Herein, we review the contemporary landscape of molecularly targeted therapies in AML with a focus on FLT3 and IDH inhibitors, identified mechanisms of resistance to these agents, and early investigations of therapies utilizing molecularly targeted agents in combination or with the addition of cytotoxic chemotherapy. This evidence concerns the gene FLT3 and acute myeloid leukemia.